![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
The MONET trial: darunavir/ritonavir monotherapy shows non-inferior efficacy to standard HAART, for patients with HIV RNA <50 copies/mL at baseline
|
|
|
JR Arribas, A Horban, J Gerstoft, G Fatkenheuer, M Nelson, N Clumeck, F Pulido, A Hill, Y van Delft, C Moecklinghoff, T Stark for the MONET Study Group
Oral Late-Breaker presentation at 5th IAS Conference
Cape Town, South Africa, July 2009
![image002.gif](../images/072109/072109-8/image002.gif)
![image004.gif](../images/072109/072109-8/image004.gif)
![image006.gif](../images/072109/072109-8/image006.gif)
![image008.gif](../images/072109/072109-8/image008.gif)
![image010.gif](../images/072109/072109-8/image010.gif)
![image012.gif](../images/072109/072109-8/image012.gif)
![image014.gif](../images/072109/072109-8/image014.gif)
![image016.gif](../images/072109/072109-8/image016.gif)
![image018.gif](../images/072109/072109-8/image018.gif)
![image020.gif](../images/072109/072109-8/image020.gif)
![image022.gif](../images/072109/072109-8/image022.gif)
![image024.gif](../images/072109/072109-8/image024.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|